# Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

> **NCT03939624** · — · COMPLETED · sponsor: **Canadian Network for Observational Drug Effect Studies, CNODES** · enrollment: 419734 (actual)

## Conditions studied

- Type2 Diabetes
- Myocardial Infarction
- Ischemic Stroke
- Cardiovascular Death
- Heart Failure
- All-Cause Mortality

## Interventions

- **DRUG:** Sodium-glucose cotransporter 2 (SGLT2) inhibitors
- **DRUG:** Dipeptidyl peptidase-4 (DPP-4) inhibitors

## Key facts

- **NCT ID:** NCT03939624
- **Lead sponsor:** Canadian Network for Observational Drug Effect Studies, CNODES
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 419734 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939624, "Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03939624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*